05-Dec-2013 - Jubilant Life Sciences has received a US FDA warning letter for its manufacturing plant in Spokane, Washington State.
05-Dec-2013 - A lawsuit alleging that the US FDA unlawfully detained a batch of acetaminophen API destined for CMO Gemini Pharmaceuticals could have significant impact on the drug industry's definition of an ‘end user.'
04-Dec-2013 - Pfizer says it is cutting 150 jobs and exiting its packaging operations at an Irish solid oral dose plant in order to increase competitiveness.
02-Dec-2013 - As part of its global streamlining strategy a second Irish Merck & Co plant has been earmarked to close but the firm says it remains committed to Ireland.
25-Nov-2013 - Pfizer says it intends to shutter a manufacturing facility in Puerto Rico just days after Merck & Co. announced it was reducing its footprint on the island.
25-Nov-2013 - A £25m (€40.5m) investment at an API facility in Scotland will allow GSK closer control over its manufacturing network efficiency, the firm says.
25-Nov-2013 - Merck Serono has announced plans to build an $80m plant for the production of diabetes and cardiovascular drugs in China.
20-Nov-2013 - Eli Lilly is investing over $700m (€518m) at a number of its insulin producing sites globally saying it is a response to the “growing diabetes epidemic.”
19-Nov-2013 - Royal DSM wants to merge its pharmaceutical products business with Patheon and has signed a deal with the latter's owner, investment group JLL Partners.
12-Nov-2013 - There are multiple ways to make amorphous dispersions in order to enhance bioavailability but spray dry dispersion (SDD) is often the most applicable, Bend Research says.
12-Nov-2013 - Concerns recently introduced import laws would cause EU-wide API shortages now appear unfounded, but European industry groups say the buffering effects of stockpiling mean it is still too early to be sure supplies will not be affected.
11-Nov-2013 - Evonik has upped its capabilities in highly potent active pharmaceutical ingredients (HPAPI) citing the increased market growth of oncology drugs.
07-Nov-2013 - Roche could restart its antibiotic development activities if a superbug busting drug candidate being developed by new partner Polyphor fulfils its early clinical promise.
06-Nov-2013 - A third Amarin supplier has confirmed it will continue to supply the firm with pharma-grade omega-3 despite a US FDA panel recommending against a label extension for the heart pill Vascepa.
05-Nov-2013 - DSM says it has not found the right partner for its pharmaceutical products business and is continuing to look for a collaborator with which it can grow in Asia.
05-Nov-2013 - An IPEC-affiliated coalition is calling on USP (US Pharmacopoeia) to allow for the determination of physiologically relevant bioaccessible elemental impurity content for pharmaceutical products and components.
04-Nov-2013 - Granules India has outlined plans to buy drug intermediate and API maker Auctus Pharma, set up an actives R&D site and announced its intention to wind up its ‘shell’ operation in Singapore.
31-Oct-2013 - Lonza says its pharmaceutical business ‘performed as expected’ in the third quarter and that its restructuring efforts – which have seen it cut nearly 800 jobs– are on track to deliver productivity gains.
30-Oct-2013 - Novasep has confirmed it will keep supplying Amarin with omega-3 API as the US FDA withdraws special status afforded to Vascepa trial.
30-Oct-2013 - API, drug intermediates and formulations firm Granules India ended the second quarter of fiscal 2013 with higher revenue and profit thanks to gains made by all three of its units.